PerkinElmer Expands Reagent Portfolio to Accelerate Biotherapeutics Drug Development

  PerkinElmer Expands Reagent Portfolio to Accelerate Biotherapeutics Drug

New AlphaLISA^® no-wash immunoassay kits enable quick and simple detectionof
                      drug impurities and toxic effects

Business Wire

WALTHAM, Mass. -- December 11, 2012

PerkinElmer, Inc., a global leader focused on improving the health and safety
of people and the environment, today announced the launch of a new range of
assay kits utilizing AlphaLISA^® technology to help improve the safety
testing, manufacturing and quality control of biotherapeutic drugs.

Biotherapeutic drug development is a rapidly growing field due to the highly
targeted and specific nature of these drugs, which are particularly beneficial
for the treatment of patients with cancer, inflammatory disease and rare
diseases. Biotherapeutics are naturally occurring molecules, such as
antibodies, recombinant proteins and vaccines, and are recognized as an
alternative to small-molecule approaches for drug development.

Regulatory requirements addressing potentially harmful side effects and
undesirable contaminants that can lead to toxic reactions or adverse immune
responses are more stringent for biotherapeutic drugs than for small molecule
drugs. PerkinElmer carefully developed these new assays to meet these more
stringent performance requirements relating to drug impurities and toxic

“PerkinElmer is continuously seeking new ways to improve human health through
the development of innovative technologies,” said Kevin Hrusovsky, President,
Life Sciences and Technology, PerkinElmer. “Adverse reactions due to drug
toxicity is a real issue that we are passionate about helping to minimize. We
are very excited to enable our customers to improve the safety and efficacy of
new biotherapeutic drugs being developed through our new assay kits which are
the latest addition to our growing biotherapeutics portfolio.”

The kits use PerkinElmer’s AlphaLISA technology  to achieve higher quality
results than the comparable ELISA (enzyme-linked immunosorbent assay)
technology in half the time, helping to accelerating the drug discovery
process. AlphaLISA technology also has a simple protocol with fewer assay
steps compared to standard ELISA, resulting in better inter- and intra-assay
precision, greatly improved coefficient of variations (CVs), and easier method
transfer to downstream departments due to reduced variability.

PerkinElmer has a portfolio of solutions across the biotherapeutics workflow,
from target identification, cloning and expression to safety testing and
quality control. The portfolio includes the LabChip^® GXII benchtop
microfluidic system for high throughput protein analysis and characterization,
and the JANUS^® BioTx Pro™ Workstation for protein purification with batch and
column chromatography capabilities.

For more information about PerkinElmer’s biotherapeutics solutions, please

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $1.9 billion in 2011, has about 7,000 employees serving
customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at


Edelman (On behalf of PerkinElmer, Inc.)
Paul Barren, 404-460-9679
Press spacebar to pause and continue. Press esc to stop.